FORM 4
☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Renaud Ronald C JR		 2. Issuer Name and Ticker or Trading Symbol

Cerevel Therapeutics Holdings, Inc. [ CERE ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
President & CEO
(Last)          (First)          (Middle)

C/O CEREVEL THERAPEUTICS HOLDINGS, INC., 222 JACOBS STREET, SUITE 200		 3. Date of Earliest Transaction (MM/DD/YYYY)

6/12/2023
(Street)

CAMBRIDGE, MA 02141		 4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)        (State)        (Zip)
Rule 10b5-1(c) Transaction Indication
☐ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) $32.72 6/12/2023  A   215749     (1)6/12/2033 Common Stock 215749 $0.00 215749 D  
Restricted Stock Units  (2)6/12/2023  A   160452     (2) (2)Common Stock 160452 $0.00 160452 D  
Performance-based Restricted Stock Units  (3)6/12/2023  A   160371     (3) (3)Common Stock 160371 $0.00 160371 D  
Explanation of Responses:
(1) 25% of this option shall vest and become exercisable on June 12, 2024, with the remainder vesting in thirty-six (36) monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
(2) The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of June 12, 2024, June 12, 2025, June 12, 2026 and June 12, 2027, subject to the Reporting Person's continued service on each such vesting date.
(3) The shares reported in this transaction represent the target number of performance-based RSUs ("PSUs") granted under the Plan. The PSUs shall vest at the end of a four-year performance period following the Grant Date based on absolute total stockholder return ("TSR") performance measured at the end of the performance period (with a payout range of 0% to 250% of the target number of PSUs, or 50% to 275% of the target number of PSUs upon a Sale Event (as defined in an Employment Agreement between the Issuer and the Reporting Person)), subject to the Reporting Person's continued service at such time. Excludes an additional 160,371 target PSUs issued on the same Grant Date that are subject to vesting based on certain relative TSR performance metrics.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Renaud Ronald C JR
C/O CEREVEL THERAPEUTICS HOLDINGS, INC.
222 JACOBS STREET, SUITE 200
CAMBRIDGE, MA 02141		X
President & CEO
Signatures
/s/ Mark Bodenrader, as Attorney-in-Fact6/14/2023
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
ARYA Sciences Acquisitio... (NASDAQ:ARYB)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more ARYA Sciences Acquisitio... Charts.
ARYA Sciences Acquisitio... (NASDAQ:ARYB)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more ARYA Sciences Acquisitio... Charts.